Pharma BD Deal Intelligence

Boehringer Ingelheim International GmbH / Ginkgo Bioworks Holdings, Inc.

2023 · Co-Development · $405M · Complete

Announcement Sentiment

Strongly positive

Ginkgo Bioworks and Boehringer Ingelheim entered a drug discovery partnership leveraging Ginkgo's metagenomic library to identify lead therapeutic molecules. Ginkgo received upfront research fees plus potential R&D, regulatory and commercial milestones totaling $405M, plus unspecified royalties.

Key facts

Announced May 08, 2023
Deal value $405M
Deal type Co-Development
Therapeutic area Multiple — diseases of high unmet need
Indications Multiple — diseases of high unmet need
Key assets Discovery & development of novel therapeutic molecules from Ginkgo's metagenomic sequence database
Mechanism Bioactive natural product discovery / synthetic biology

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals